OA
Oak Associates Portfolio holdings
AUM
$1.53B
1-Year Return
20.93%
This Quarter Return
+24.87%
1 Year Return
+20.93%
3 Year Return
+113.44%
5 Year Return
+164.39%
10 Year Return
+515.4%
AUM
$1.49B
AUM Growth
+$270M
(+22%)
Cap. Flow
-$11.2M
Cap. Flow
% of AUM
-0.75%
Top 10 Holdings %
Top 10 Hldgs %
44.65%
Holding
141
New
11
Increased
24
Reduced
31
Closed
6
Top Buys
| 1 |
Digital Realty Trust
DLR
|
$25.7M |
| 2 |
Meta Platforms (Facebook)
META
|
$5.59M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$5.54M |
| 4 |
Akamai
AKAM
|
$2.14M |
| 5 |
AbbVie
ABBV
|
$1.85M |
Top Sells
| 1 |
Microsoft
MSFT
|
$18.8M |
| 2 |
Alphabet (Google) Class C
GOOG
|
$9.93M |
| 3 |
GSK
GSK
|
$5.55M |
| 4 |
IBM
IBM
|
$3.77M |
| 5 |
PepsiCo
PEP
|
$2.63M |
Sector Composition
| 1 | Technology | 39.36% |
| 2 | Healthcare | 16.41% |
| 3 | Communication Services | 13.59% |
| 4 | Consumer Discretionary | 13.43% |
| 5 | Financials | 8.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Medtronic
MDT
$119B
| $6.75M | 0.45% |
73,611
| – | – |
|
|
52
Vertex Pharmaceuticals
VRTX
$102B
| $5.54M | 0.37% |
+19,080
| New | +$5.54M |
|
53
Biogen
BIIB
$20.6B
| $5.44M | 0.37% |
20,323
+15
| +0.1% | +$4.01K |
|
54
Capital One
COF
$142B
| $5.11M | 0.34% |
81,596
| – | – |
|
55
Bank of New York Mellon
BK
$73.1B
| $5.05M | 0.34% |
130,530
| – | – |
|
56
Paychex
PAYX
$48.7B
| $4.87M | 0.33% |
64,230
| – | – |
|
57
Quest Diagnostics
DGX
$20.5B
| $4.64M | 0.31% |
40,700
| – | – |
|
58
Assurant
AIZ
$10.7B
| $4.58M | 0.31% |
44,350
| – | – |
|
59
Synchrony
SYF
$28.1B
| $3.77M | 0.25% |
170,235
| – | – |
|
60
Valero Energy
VLO
$48.7B
| $3.33M | 0.22% |
56,550
-20,000
| -26% | -$1.18M |
|
61
Charles River Laboratories
CRL
$8.07B
| $2.98M | 0.2% |
17,115
-880
| -5% | -$153K |
|
62
UnitedHealth
UNH
$286B
| $2.73M | 0.18% |
9,250
| – | – |
|
63
SolarEdge
SEDG
$2.04B
| $2.71M | 0.18% |
19,490
-790
| -4% | -$110K |
|
64
PayPal
PYPL
$65.2B
| $2.66M | 0.18% |
15,260
| – | – |
|
65
Jack Henry & Associates
JKHY
$11.8B
| $2.63M | 0.18% |
14,315
+1,450
| +11% | +$267K |
|
66
Sanofi
SNY
$113B
| $2.22M | 0.15% |
43,380
-20,040
| -32% | -$1.02M |
|
67
Everest Group
EG
$14.3B
| $2.19M | 0.15% |
10,600
| – | – |
|
68
Cardinal Health
CAH
$35.7B
| $2.16M | 0.15% |
41,395
-13,725
| -25% | -$716K |
|
69
Novo Nordisk
NVO
$245B
| $2.13M | 0.14% |
64,920
-37,560
| -37% | -$1.23M |
|
70
Elevance Health
ELV
$70.6B
| $1.88M | 0.13% |
7,155
+5,415
| +311% | +$1.42M |
|
|
71
AbbVie
ABBV
$375B
| $1.85M | 0.12% |
+18,794
| New | +$1.85M |
|
72
Merck
MRK
$212B
| $1.84M | 0.12% |
24,880
-1,603
| -6% | -$118K |
|
73
Cohu
COHU
$950M
| $1.8M | 0.12% |
103,636
+12,935
| +14% | +$224K |
|
74
United Therapeutics
UTHR
$18.1B
| $1.74M | 0.12% |
14,405
+2,555
| +22% | +$309K |
|
75
Diodes
DIOD
$2.46B
| $1.61M | 0.11% |
31,670
+3,065
| +11% | +$155K |
|